Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors

Journal of Neurosurgery

Volumn 91, Issue 6, 1999, Pages 935-946

  Morford, Lorri A ^a   Dix, Amy R ^a   Brooks, William H ^a   Roszman, Thomas L ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cytokine; Glioma; Monocyte; T lymphocyte

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOTOXIN; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CELLULAR IMMUNODEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GENE ACTIVATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INTRACRANIAL TUMOR; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE;

EID: 0032749967     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1999.91.6.0935     Document Type: Article

References (58)

1. Adachi Y, Oyaizu N, Than S, et al: IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. Correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 157:4184-4193, 1996
2. Amasaki Y, Kobayashi S, Takeda T, et al: Up-regulated expression of Fas antigen (CD95) by peripheral naïve and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol 99:245-250, 1995
3. Bodmer S, Strommer K, Frei K, et al: Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J Immunol 143: 3222-3229, 1989
4. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Invest 21 (Suppl 97): 77-89, 1968
5. Braun DP, Penn RD, Flannery AM, et al: Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery 10:203-209, 1982
6. Brooks WH, Latta RB, Mahaley MS, et al: Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status. J Neurosurg 54:331-337, 1981
7. Brooks WH, Netsky MG, Normansell DE, et al: Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136:1631-1647, 1972
8. Brooks WH, Roszman TL, Mahaley MS, et al: Immunobiology of primary intracranial tumors. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin Exp Immunol 29:61-66, 1977
9. Brooks WH, Roszman TL, Rogers AS: Impairment of rosetteforming T lymphocytes in patients with primary intracranial tumors. Cancer 37:1869-1873, 1976
10. Castelli MG, Chiabrando C, Fanelli R, et al: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49:1505-1508, 1989
11. Clerici M, Balotta C, Salvaggio A, et al: Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression of HIV infection. Blood 88:574-579, 1996
12. Clerici M, Sarin A, Berzofsky JA, et al: Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T-cells, modulated by cytokines and effected by lymphotoxin. AIDS 10:603-611, 1996
13. Clerici M, Sarin A, Coffman RL, et al: Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 91:11811-11815, 1994
14. Clerici M, Shearer GM: The Thl-Th2 hypothesis of HIV infection: new insights. Immunol Today 15:575-581, 1994
15. H2 switch is a critical step in the etiology of HIV infection. Immunol Today 14:107-111, 1993
16. Clerici M, Shearer GM, Clerici E: Cytokine dysregulation in invasive cervical carcinoma and other human neoplasia: time to consider the Th1/Th2 paradigm. J Natl Cancer Inst 90: 261-263, 1998
17. Couldwell WT, Dore-Duffy P, Apuzzo ML, et al: Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 33:89-96, 1991
18. Das G, Vohra H, Rao K, et al: Leishmania donovani infection of a susceptible host results in CD4+ T-cell apoptosis and decreased Thl cytokine production. Scand J Immunol 49: 307-310, 1999
19. de Martin R, Haendler B, Hofer-Warbinek R, et al: Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 6:3673-3677, 1987
20. Elgert KD, Alleva DG, Mullins DW: Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290, 1998
21. Elliott L, Brooks W, Roszman T: Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 78:919-922, 1987
22. Elliott LH, Brooks WH, Roszman TL: Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J Neurosurg 67:231-236, 1987
23. Elliott LH, Brooks WH, Roszman TL: Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132:1208-1215, 1984
24. Elliott LH, Brooks WH, Roszman TL: Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest 86:80-86, 1990
25. Elliott LH, Brooks WH, Roszman TL: Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor. J Neurooncol 14:1-7, 1992
26. Elliott LH, Carlson SL, Morford LA, et al: Preparation, characterization, and use of human and rodent lymphocytes, monocytes, and neutrophils, in Phillips MI, Evans D (eds): Neuroimmunology. Methods in Neurosciences, Vol 24. San Diego: Academic Press, 1995, pp 115-150
27. Flora PK, Gregory CD: Recognition of apoptotic cells by human macrophages: inhibition by monocyte/macrophage-specific monoclonal antibody. Eur J Immunol 24:2625-2632, 1994
28. Hishii M, Nitta T, Ishida H, et al: Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37:1160-1167, 1995
29. Huettner C, Czub S, Kerkau S, et al: Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17:3217-3224, 1997
30. Huettner C, Paulus W, Roggendorf W: Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317-322, 1995
31. Jondal M, Holm G, Wigzell H: Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med 136:207-215, 1972
32. Landay AL, Clerici M, Hashemi F, et al: In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis 173:1085-1091, 1996
33. Levy NL: Cell-mediated cytotoxicity and serum-mediated blocking: evidence that their association determinants on human tumor cells are different. J Immunol 121:916-922, 1978
34. Mahaley MS Jr, Brooks WH, Roszman TL, et al: Immunobiology of primary intracranial tumors. Part 1: Studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 46:467-476, 1977
35. Morford LA, Elliott LH, Carlson SL, et al: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415-4425, 1997
36. Münz C, Naumann U, Grimmel C, et al: TGF-β-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. Eur J Immunol 29:1032-1040, 1999
37. Nitta T, Hishii M, Sato K, et al: Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649:122-128, 1994
38. Pittner BT, Mullins MW, Reid S, et al: An in vitro approach for the characterization of the cycling B cell response. In Vitro Cell Dev Biol Anim 34:421-429, 1998
39. Reid S, Cross R, Snow EC: Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage. viability and apoptosis. J Immunol Methods 192:43-54, 1996
40. Reinhard G, Noll A, Schlebusch H, et al: Shifts in the Th1/Th2 balance during human pregnancy correlate with apoptotic changes. Biochem Biophys Res Commun 245:933-938, 1998
41. Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370-374, 1991
42. Roszman TL, Brooks WH: Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 39:395-402, 1980
43. Roszman TL, Brooks WH, Elliott LH: Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin-binding lymphocyte subpopulations in patients with cerebral tumors. Cancer 50:1273-1279, 1982
44. Roszman TL, Brooks WH, Elliott LH: Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor. J Neurosurg 67:874-879, 1987
45. Roszman TL, Brooks WH, Steele C, et al: Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J Immunol 134: 1545-1550, 1985
46. Roussel E, Gingras MC, Grimm EA, et al: Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105:344-352, 1996
47. Sarin A, Conan-Cibotti M, Henkart PA: Cytotoxic effects of TNF and lymphotoxin on T lymphoblasts. J Immunol 155: 3716-3718, 1995
48. Siepl C, Bodmar S, Frei K, et al: The glioblastoma-derived T-cell suppressive factor/transforming growth factor-β2 inhibits T-cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593-600, 1988
49. Sundström C, Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565-577, 1976
50. Taga K, Tosata G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148:1143-1148, 1992
51. Welch WC, Morrison RS, Gross JL, et al: Morphologic, immunologic, biochemical, and cytogenetic characteristics of the human glioblastoma-derived cell line, SNB-19. In Vitro Cell Dev Biol Anim 31:610-616, 1995
52. Weller M, Constam DB, Malipiero U, et al: Transforming growth factor-β2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24:1293-1300, 1994
53. Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21:128-151, 1995
54. Weller M, Malipiero U, Groscurth P, et al: T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-β2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Exp Cell Res 221:395-403, 1995
55. Wrann M, Bodmer S, de Martin R, et al: T cell suppressor factor from human glioblastoma cells is a 12.5 kD protein closely related to transforming growth factor-β. EMBO J 6: 1633-1636, 1987
56. Yang BC, Wang YS, Lin LC, et al: Induction of apoptosis and cytokine gene expression in T-cell lines by sera of patients with systemic lupus erythematosus. Scand J Immunol 45:96-102, 1997
57. Young HF, Sakalas R, Kaplan AM: Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol 5:19-23, 1976
58. Zou JP, Morford LA, Chougnet C, et al: Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:4882-4892, 1999